NCT04189315撤回4 期
A Phase 4, Randomized, Multicenter, Open-Label, 2-Dosage Regimen, Safety and Tolerability, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 撤回
- 主要终点
- Change From Baseline To Week 36 In Plasma Concentrations Of Inorganic Pyrophosphate (PPi) In Group 1
研究概览
简要总结
The study will evaluate safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 2 different doses (approved dose and lower dose) of asfotase alfa in adult participants with pediatric-onset hypophosphatasia (HPP).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female aged ≥ 18 years at the time of signing the informed consent form
- •Clinical diagnosis of pediatric-onset HPP based on signs and symptoms consistent with HPP
- •Past medical history that includes at least one nonvertebral fracture (or pseudofracture) incurred without evidence of significant trauma.
- •The presence of a current fracture is not necessary, but for participants with current unhealed fracture(s) or pseudofracture(s) of the lower extremity(ies) (that is, femoral, tibial, fibular, metatarsal) documentation must be provided of the presence of these fractures for at least 3 months prior to screening (with or without surgical intervention)
排除标准
- •Medical condition, serious concurrent or recurrent illness and/or injury, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance or the assessment of study endpoints, including all protocol required evaluations and follow up activities, or may put the patient at risk
- •Primary or secondary hyperparathyroidism or hypoparathyroidism
- •History of hypersensitivity to any ingredient contained in asfotase alfa
- •Oral bisphosphonate use within 6 to 12 months (depending on the half-life of the drug as assessed by the investigator) and intravenous (IV) bisphosphonate use within 12 months prior to screening
- •Denosumab use within 18 months prior to screening
- •Asfotase alfa use within 6 months prior to screening
- •Teriparatide/parathyroid hormone analog use within 2 months prior to screening
- •Treatment with strontium or sclerostin inhibitors within 6 months prior to the first dose of study drug
- •Vitamin B6 use for at least 2 weeks prior to screening
- •Serum 25-hydroxy (25-OH) vitamin D below 20 nanogram (ng)/milliliter (mL), with repletion and recheck allowed at screening (results from local laboratory may be used if within 4 weeks of screening)
- •Female patients who are pregnant, planning to become pregnant, or breastfeeding
研究组 & 干预措施
Group 1 Asfotase Alfa
Experimental
Participants will be administered asfotase alfa per approved dose for 36 weeks.
干预措施: asfotase alfa (Drug)
Group 2 Asfotase Alfa
Experimental
Participants will be administered asfotase alfa per approved dose for 12 weeks and then asfotase alfa at a lower dose for 24 weeks.
干预措施: asfotase alfa (Drug)
结局指标
主要结局
Change From Baseline To Week 36 In Plasma Concentrations Of Inorganic Pyrophosphate (PPi) In Group 1
时间窗: Baseline, Week 36
次要结局
- Change From Baseline To Week 36 In Plasma Concentrations Of PPi In Group 2(Baseline, Week 36)
- Change From Baseline To Week 36 In The 36-item Short-Form Survey (SF-36) Physical Component Summary (PCS) Score In Groups 1 And 2(Baseline, Week 36)
- Change From Baseline To Week 36 In The Repeated Chair Stand Test (A Component Of The Short Physical Performance Battery [SPPB]) In Groups 1 And 2(Baseline, Week 36)
研究者
相似试验
已完成
4 期
A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL)Uncontrolled GoutChronic GoutNCT04762498Amgen54
已完成
4 期
Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric PatientsPathological ProcessesNCT01092754Guerbet100
已完成
2 期
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity DisorderAttention Deficit Hyperactivity Disorder (ADHD)NCT02402166Shire24
已完成
4 期
Safety, Tolerability, Pharmacokinetics and Efficacy of ARCOPlasmodium FalciparumMalaria, FalciparumNCT01930331Ifakara Health Institute60
暂停
2 期
Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TBNCT02354014Janssen Research & Development, LLC60